Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Postma

Showing results (61-70 of 135) with videos related to

Pageof 14
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccine in the United StatesP T De Boer, R J Pitman, B Macabeo, et al.
Drugs & Aging|October 24, 2000
Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidenceM J Postma, R M Baltussen, M L Heijnen, et al.
Vaccine|May 4, 2004
Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands)M J Postma, J M Bos, Ph Beutels, et al.
Current Medical Research and Opinion|January 29, 2015
Does a cardiovascular event change adherence to statin treatment in patients with type 2 diabetes? A matched cohort designF M de Vries, P Denig, S Vegter, et al.
Current Pharmaceutical Design|August 5, 2008
HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populationsA Tramarin, N Gennaro, F A Compostella, et al.
Vaccine|June 29, 2013
Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into accountJ Luttjeboer, T A Westra, J C Wilschut, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 12, 2023
Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the NetherlandsS W Quist, A J Postma, K J Myrén, et al.
Vox Sanguinis|August 31, 2002
Pharmaco-economics of blood transfusion safety: review of the available evidenceM van Hulst, J T M de Wolf, U Staginnus, et al.
Statistics in Medicine|June 29, 2007
Estimation and prediction of the HIV-AIDS-epidemic under conditions of HAART using mixtures of incubation time distributionsS H Heisterkamp, R de Vries, H G Sprenger, et al.
Current Medical Research and Opinion|October 20, 2015
Effects of targeting disease and medication management interventions towards patients with COPDJ F M van Boven, A G G Stuurman-Bieze, E G Hiddink, et al.
Pageof 14

Showing results (61-70 of 135) with videos related to

Sort By:
Pageof 14
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccine in the United StatesP T De Boer, R J Pitman, B Macabeo, et al.
Drugs & Aging|October 24, 2000
Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidenceM J Postma, R M Baltussen, M L Heijnen, et al.
Vaccine|May 4, 2004
Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands)M J Postma, J M Bos, Ph Beutels, et al.
Current Medical Research and Opinion|January 29, 2015
Does a cardiovascular event change adherence to statin treatment in patients with type 2 diabetes? A matched cohort designF M de Vries, P Denig, S Vegter, et al.
Current Pharmaceutical Design|August 5, 2008
HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populationsA Tramarin, N Gennaro, F A Compostella, et al.
Vaccine|June 29, 2013
Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into accountJ Luttjeboer, T A Westra, J C Wilschut, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 12, 2023
Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the NetherlandsS W Quist, A J Postma, K J Myrén, et al.
Vox Sanguinis|August 31, 2002
Pharmaco-economics of blood transfusion safety: review of the available evidenceM van Hulst, J T M de Wolf, U Staginnus, et al.
Statistics in Medicine|June 29, 2007
Estimation and prediction of the HIV-AIDS-epidemic under conditions of HAART using mixtures of incubation time distributionsS H Heisterkamp, R de Vries, H G Sprenger, et al.
Current Medical Research and Opinion|October 20, 2015
Effects of targeting disease and medication management interventions towards patients with COPDJ F M van Boven, A G G Stuurman-Bieze, E G Hiddink, et al.
Pageof 14